Scientific publications
PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma
Paiva B(1), Azpilikueta A(2), Puig N(3), Ocio EM(3), Sharma R(4), Oyajobi BO(4), Labiano S(2), San-Segundo L(3), Rodriguez A(5), Aires-Mejia I(3), Rodriguez I(2), Escalante F(6), de Coca AG(7), Barez A(8), San Miguel JF(1), Melero I(1).
(1) [1] Clinica Universidad de Navarra, Pamplona, Spain [2] Centro de Investigaciones Medicas Aplicadas (CIMA), Pamplona, Spain [3] Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain.
(2) Centro de Investigaciones Medicas Aplicadas (CIMA), Pamplona, Spain.
(3) Hospital Universitario de Salamanca, IBSAL, IBMCC (USAL-CSIC), Salamanca, Spain.
(4) University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
(5) Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain.
(6) Complejo Hospitalario de Leon, Leon, Spain.
(7) Hospital Clinico Universitario de Valladolid, Valladolid, Spain.
(8) Hospital Nuestra Señora de Sonsoles, Avila, Spain.
Despite remarkable therapeutic improvement in multiple myeloma (MM), prognosis is very poor once patients become refractory to or ineligible for proteasome inhibitors and immunomodulatory drugs.
Accordingly, new drugs are clearly needed for this patient population, and extensive efforts are leading to a new breed of antimyeloma drugs. In this regard, the PD-1/PD-L1 axis has recently emerged as a master immune checkpoint that controls antitumor immune responses against many neoplasms.
CITATION Leukemia. 2015 Mar 17. doi: 10.1038/leu.2015.79.
Our authors
